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Is the Second Sodium Pump Electrogenic?
Jesu´s R. del Castillo, Luz E. Thomas, Miguel A. Rocafull.
IVIC, Caracas, Venezuela, Bolivarian Republic of.
Transepithelial sodium transport is a process that involves Naþ entry across the
apical membrane of the epithelial cell following its electro-chemical gradient
and its active extrusion at the basolateral plasma membrane by two sodium
pumps: The Na/K-pump, which depends on Kþ, is inhibited by ouabain and in-
sensitive to furosemide; and the Second Sodium pump, which is Kþ-indepen-
dent, insensitive to ouabain but inhibited by furosemide (J. Gen. Physiol.
51:303s-314s, 1968; Pflu¨gers Archiv Eur J Physio 316:1-25, 1970; Biochim
Biophys Acta 394:281-292, 1975). Both transport mechanisms are associated
with two ATPases present in the basolateral plasma membrane of the epithelial
cells with similar functional characteristics, the Naþ/Kþ-ATPase and the Naþ-
ATPase, respectively (Biochim Biophys Acta 1808:1684-1700, 2011; Pflu¨gers
Archiv Eur J Physio. 316:1-25, 2012). The Naþ/Kþ-pump is electrogenic; it ex-
changes 3 internal Naþ by 2 external Kþ producing a net charge movement.
The Second pump transports Naþ with Cl and water. It has been suggested
that this pump could be electrogenic. The Naþ charge transfer would induce
Cl- movement and osmotic movement of water following the movement of
both Naþ and Cl across the membrane. We have evaluated electrical param-
eters of the basolateral plasma membranes of MDCK cells cultured on Trans-
well in Ussing chambers, using amphotericin as apical permeabilizing agent.
Our results confirm that the Naþ/Kþ-pump is electrogenic and that the Second
sodium pump is electroneutral, coupling the active Naþ transport to a specific
Cl movement through a particular conductive pathway.
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Proton Current through Stalled Na/K-ATPase Pumps: Three Residues
Point to a Possible Route and Mechanism
Natascia Vedovato, David C. Gadsby.
The Rockefeller University, New York, NY, USA.
Na/K pumps export 3 Nai ions for every 2 Ko ions imported, and so generate
outward current. But Na/K pumps stalled in Ko-free and Nao-free solution
pass an inward current that is greatly augmented by lowering pHo to 6. We stud-
ied this inward current in Xenopus oocytes expressing Xenopus a1 Na/K pumps
made relatively ouabain-resistant by C113Y or Q120R/N131D mutations. The
inward current was abolished by arresting pumps with 10 mM ouabain or by
activating them with Ko, but not by obstructing either end of the principal
ion transport pathway - by BeFx action at the cytoplasmic side, or by modifica-
tion of an introduced target Cys at the extracellular side. We explored whether,
instead, a conformational equilibrium might expose one or more protonatable
side chains alternately to extracellular and cytoplasmic solutions, allowing pro-
ton current flow down a proton electrochemical gradient. One at a time, we neu-
tralized (E>Q, D>N) carboxylate side chains in cation coordination sites I and
II (E336 in TM4; E788 in TM5; D813 and D817 in TM6) and in the proposed
third-Na binding site (D935 in TM8; E963 in TM9), and mutated (H>A/N)
a nearby His (H921 in TM8). Despite these mutations, low pHo robustly acti-
vated inward current in all but D935N, E963Q, and D935N/E963Q stalled
pumps. D935 and E963 are 9-10 A˚ apart in the E2P.2K Na/K-ATPase crystal
structures, with a Tyr (Y780 in TM5) equidistant between them with its side
chain pointing toward E963. The mutation Y780F almost abolished low-pHo-
activated inward current in stalled Na/K pumps. We suggest that, in stalled
Na/K pumps, E963 recruits an extracellular proton and, after a conformational
change, delivers it (via Y780) to D935, which releases it to the cytoplasm, gen-
erating inward current. [NIH HL36783]
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An Oxalate/Citrate Homeostatic Pathway: The Oxalate Slc26a6 and
Citrate NaDC-1 Transporters Interplay
Ehud Ohana, Nikolay Shcheynikov, Shmuel Muallem.
NIH/NIDCR, Bethesda, MD, USA.
Stone formation is one of the most common urologic diseases in industrialized
societies, most prevalent in the kidney and salivary glands. A predominant
component of kidney stones is the Ca2þ-oxalate crystals found in more than
70% of cases. The stones are formed when renal oxalate and Ca2þ loads in-
crease as a result of their increased level in the filtrate. Stone formation is nor-
mally prevented by chelation of urinary Ca2þ by citrate. A change in the
oxalate/citrate balance is also required for stone formation. A link between
Ca2þ-oxalate kidney stones and the oxalate transporter Slc26a6 has been de-
scribed in Slc26a6-/- mice, where the major phenotype is Ca2þ-oxalate stoneformation. Nevertheless, the molecular mechanism that maintains oxalate/
citrate balance remains unknown. Here, we report in-vivo and in-vitro interplay
between the oxalate transporter Slc26a6 and the citrate transporter NaDC-1 to
achieve a balanced citrate/oxalate homeostasis. Thus, Slc26a6 markedly in-
hibits NaDC-1 to limit citrate absorption at increased oxalate loads. At the
same time, NaDC-1 activates Slc26a6 to allow oxalate clearance when citrate
load is high. The interaction between the oxalate and citrate transporters is me-
diated by the Slc26a6 STAS domain and the NaDC-1 first intracellular loop.
The STAS domain and the first intracellular loop are sufficient to mediate
the reciprocal regulation. Accordingly, deletion of Slc26a6 in mice enhanced
the activity of the native NaDC-1. These findings reveal a molecular pathway
that senses and tightly regulates renal oxalate and citrate that likely function in
other organs, such as the salivary glands, to guard against Ca2þ-oxalate stone
formation.
117-Plat
Role of SLC6A14 as a Modifier of Cystic Fibrosis Phenotype
Saumel Ahmadi, Catherine Luk, Timothy Chung, Rupinder Mangat,
Johanna Rommens, Christine Bear.
Hospital for Sick Children, Toronto, ON, Canada.
Cystic Fibrosis (CF) is considered to be a single gene disorder, most commonly
the result of a F508del mutation in the CFTR gene. However, patients homo-
zygous for F508del mutation show a considerable variation in disease severity.
Consistent with this observation, recent genome wide association studies iden-
tified secondary genes that modify disease. A SNP in the putative promoter re-
gion of SLC6A14 gene showed the highest significance (p=1.28x1012).
SLC6A14 is a cationic/neutral amino acid transporter, which transports
2Naþ, 1 Cl and a basic/neutral amino-acid into the cell from the apical surface
of intestinal/bronchial epithelium. We hypothesize that expression of
SLC6A14 is protective against meconium ileus, a CF phenotype detected at
birth. To test this hypothesis we over-expressed SLC6A14 in BHK cells stably
expressing either WT or F508del-CFTR. We measured CFTR channel activity
using the halide sensitive fluorophore, SPQ. We found that CFTR function is
enhanced with over-expression of SLC6A14 in cells expressing WT CFTR
or F508del CFTR (after rescue of its trafficking defect), (p<0.05). This sug-
gests a possible functional interaction between SLC6A14 and CFTR. We
also monitored the functional interaction of SLC6A14 and CFTR in Caco-2
cells, an intestinal cell line that endogenously expresses both CFTR and
SLC6A14. Caco-2 cells form three-dimensional, cyst-like cultures wherein
CFTR mediated secretion determines the volume of its internal cavity. We
found that the area of the cyst cavity increases upon cAMP stimulation of
CFTR stimulation by 5.5 fold and that this expansion was decreased by 44%
in the presence of the SLC6A14 inhibitor (a-methyltryptophan). These results
suggest that SLC6A14 exerts a positive effect on regulated CFTR function and
future studies will explore the possibility that agonists of SLC6A14 could con-
stitute a means for therapeutic intervention.
(Studies supported by grants to C.E.B and J.M.R. from CFC, CIHR)
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Functional Evaluation of Autism Associated Mutations in Slc9A9 (NHE9)
Kalyan C. Kondapalli1, Anniesha Hack1, Maya Schushan2, Nir Ben-Tal2,
Rajini Rao1.
1Johns Hopkins University, Baltimore, MD, USA, 2Tel-Aviv University,
Tel-Aviv, Israel.
A number of neurological disorders including autism, have recently been
linked to mutations in a subgroup of intracellular Naþ(Kþ)/Hþ exchangers,
which include NHE6 and NHE9. In this work, we examine the functional con-
sequence of missense mutations in NHE9 associated with autism. In an attempt
to determine mutations that are likely to actually be disease-causing amongst
those variants identified by genetic studies, we used a unique homology mod-
eling approach in combination with evolutionary analysis. We constructed
a model for NHE9 using the NHE1 model as the structural template. Based
on this analysis we chose mutations reported for the highly conserved L236,
S438 and the moderately conserved V176 residues for further study. As a first
approach, we used a yeast system to screen these NHE9 variants. Next, NHE9
mutations were expressed in mouse primary astrocytes for functional evalua-
tion. NHE9 localized to early and recycling endosomes where it altered endo-
somal pH to effect the trafficking of glutamate transporter (GLAST) and
consequently glutamate uptake. Further, we observed that this is not restricted
to the astrocyte specific transporter as the uptake of transferrin by the transfer-
rin receptor was also altered. Unlike the wild type protein, autism associated
NHE9-mutants failed to show this effect. Taken together, these studies provide
for the first time, a cellular assessment of the NEH9 mutations identified in au-
tistic patients.
